Low-dose enoximone improves exercise capacity in chronic heart failure∗∗A list of the Enoximone Study Group Members and institutional affiliations is provided in the appendix.

This publication has 33 references indexed in Scilit:

• Tolerability and efficacy of carvedilol in patients with New York Heart Association class IV heart failure
  Journal of the American College of Cardiology, 1999
• Pharmacologic and Hemodynamic Effects of Combined β-Agonist Stimulation and Phosphodiesterase Inhibition in the Failing Human Heart
  Chest, 1995
• Direct evidence for cross-activation of cGMP-dependent protein kinase by cAMP in pig coronary arteries.
  Journal of Biological Chemistry, 1992
• Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts.
  Journal of Clinical Investigation, 1991
• Pharmacology and Pharmacokinetics of Enoximone
  Cardiology, 1990
• Impaired chronotropic response to exercise in patients with congestive heart failure. Role of postsynaptic beta-adrenergic desensitization.
  Circulation, 1989
• The -adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure
  European Heart Journal, 1989
• Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure
  Journal of the American College of Cardiology, 1987
• Inotropic effect of enoximone in patients with severe heart failure: Demonstration by left ventricular end-systolic pressure-volume analysis
  Journal of the American College of Cardiology, 1987
• Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response.
  Circulation, 1986